Organoidsciences Ltd. (KOSDAQ:476040)

South Korea · Delayed Price · Currency is KRW

4,960.00

-40.00 (-0.80%)

At close: Nov 13, 2026

Market Cap	32.67B -83.9%
Revenue (ttm)	2.29B -9.2%
Net Income	-18.45B
EPS	-2,805.24
Shares Out	6.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,675
Open	5,020.00
Previous Close	5,000.00
Day's Range	4,955.00 - 5,320.00
52-Week Range	4,930.00 - 48,500.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea. [Read more]

Industry Pharmaceutical Preparations

Founded 2018

Employees 99

Stock Exchange KOSDAQ

Ticker Symbol 476040

Full Company Profile

Financial Performance

In 2025, Organoidsciences's revenue was 2.41 billion, an increase of 23.21% compared to the previous year's 1.95 billion. Losses were -15.37 billion, 36.6% more than in 2024.

Financial Statements